{"nctId":"NCT04142983","briefTitle":"Tdap Vaccine Safety for Plasma Donors","startDateStruct":{"date":"2020-02-03","type":"ACTUAL"},"conditions":["Tetanus"],"count":110,"armGroups":[{"label":"Study Group","type":"EXPERIMENTAL","interventionNames":["Biological: Adacel"]}],"interventions":[{"name":"Adacel","otherNames":["Tdap Vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ages 18 to 63 years\n* Females of childbearing potential who agree to employ adequate birth control measures during the study\n* Signed the informed consent form (ICF)\n* Met all of the criteria required by GCAM to be a Normal Source Plasma donor\n* Subject is not participating in any other immunization program\n\nExclusion Criteria:\n\n* Subject is pregnant\n* Subject has a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data\n* Subject has repeated reactions or hypersensitivity to components in the vaccine (e.g., thimerosal, latex, etc.)\n* Subject has history of a severe reaction to any immunization\n* Subject has a history of Guillain-Barré Syndrome\n* The Investigator concludes that the anticipated vaccination site (deltoid area) is not suitable for AE assessment","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"63 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are defined as an adverse event occurring after first study treatment. A serious TEAE was defined as an AE that resulted in any of the following outcomes: death; life-threatening; inpatient hospitalization or prolongation of hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, an important medical event that based on appropriate medical judgment may jeopardize the subject and may require medical or surgical intervention to prevent one of the aforementioned outcomes.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-tetanus Antibody Titers in Participants Over Time","description":"Anti-tetanus antibody titer levels after each vaccination presented at geometric means (GeoMean) over time.","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Post Vaccination Anti-tetanus Antibody Range Levels","description":"The numbers and percentages of participants whose post vaccination antibody levels were \\<5 IU/mL; ≥5 IU/mL to 10 IU/mL; \\>10 IU/mL to 15 IU/mL; and, \\>15 IU/mL after each vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"33","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Injection site pain","Injection site bruising","Red blood cells urine positive","Urine leukocyte esterase positive","Injection site erythema"]}}}